Agilent Technologies Inc. has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold standard for acquiring, analyzing, and reporting flow data across diverse domains?from basic research to drug discovery and therapy development. The NovoCyte Opteon represents a significant leap forward in flow cytometry technology, with configurations ranging from three to five lasers and support for up to 73 high-quality detectors.

It meets researchers? needs for sophisticated, large-panel flow cytometry assays while maintaining the easy-to-use features of the NovoCyte portfolio. Researchers can now explore cellular mysteries with unparalleled precision, simultaneously analyzing over 40 markers, providing great flexibility in flow panel design.

Flow cytometry is a crucial technology employed globally, spanning academic centers, biotech firms, and pharmaceutical companies. The NovoCyte Opteon assumes a pivotal role, empowering researchers with advanced spectral capabilities, user-friendly design, and customizable features to align with specific research requirements. Advanced engineering with proprietary technology ensures optimized light collection and electronic signal collection, real-time monitoring, and consistent, reliable data acquisition.

Agilent will officially unveil the NovoCyte Opteon at the CYTO 2024 Conference in Edinburgh, Scotland, happening May 4 ? 8, 2024.